Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.
Company has Babu A Kallivayalil & Co as its auditors. As on 30-09-2024, the company has a total of 64.71 Crore shares outstanding.FACT Share Price Today is Rs. 818.70 as on 14 Nov, 2024, 03:59 PM IST.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback